INVITRX Collaboration Update: GENRÊVER — Made in the U.S., Sold in the U.S.
Initial GENRÊVER-branded product line-up identified for manufacture at INVITRX’s U.S. facility using INVITRX ingredients; manufacturing targeted to commence within 2026
Key Facts
- Company
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Ticker
- Nasdaq: BIOT
- Announcement Date
- Category
- NEWS
- Source
- Official BIOT announcement
Tokyo, Japan – September 4, 2026 | Detailed companion to the Company’s operational update press release of the same date
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (the “Company” or “Instinct Bio”) today provided a progress update on its collaboration with Invitrx Therapeutics, Inc. (“INVITRX”), announced on July 30, 2026. The Company and INVITRX have identified an initial GENRÊVER-branded cosmetic product line-up for potential manufacture in the United States. Manufacturing is currently targeted to commence within 2026, subject to final formulation, manufacturing scheduling, regulatory considerations and related commercial arrangements.
This page explains how the U.S. business is structured, why the Company is manufacturing in the United States rather than exporting from Japan, and where the project stands today.
“Made in the U.S., Sold in the U.S.” — Japanese formulation, American manufacturing, local sales
How the U.S. model works
Step 1
Formulate in Japan
The Company’s subsidiary Artisans Production Co., Ltd. provides the GENRÊVER formulations, drawing on the Company’s Japanese formulation expertise.
Step 2
INVITRX ingredients
INVITRX — the Company’s ingredient supplier for approximately six years — supplies the ingredients for the U.S. products.
Step 3
Manufacture in the U.S.
Products are manufactured at INVITRX’s U.S. GMP-certified facility, subject to applicable regulatory requirements.
Step 4
Sell in the U.S.
The products are sold in the U.S. market under the GENRÊVER trademark as premium Japanese-origin cosmetics.
The key point is that the finished products are not exported from Japan. They are made and sold in the United States. The Company contributes the brand and the formulation; INVITRX contributes ingredients and manufacturing; and the product reaches U.S. consumers as a locally made product with Japanese design.
Why manufacture in the United States
Proximity to the market
Manufacturing where the product is sold shortens lead times and simplifies replenishment compared with shipping finished goods across the Pacific.
A partner the Company already knows
The Company has purchased ingredients from INVITRX for approximately six years. The collaboration extends an existing commercial relationship rather than starting a new one.
GMP-certified production
INVITRX’s facility is GMP-certified in the United States, which is the manufacturing standard the Company requires for GENRÊVER products regardless of where they are made.
What has happened since July 30, 2026
On July 30, 2026, the Company’s subsidiaries Instinct Brothers Co., Ltd. and Artisans Production Co., Ltd. entered into a Memorandum of Agreement with INVITRX. Since then, the two companies have worked through product planning for the U.S. market and have now identified an initial GENRÊVER-branded product line-up for potential manufacture at INVITRX’s facility. The next steps are final formulation for each product, manufacturing scheduling, confirmation of regulatory considerations, and the related commercial arrangements.
Background: the two pillars of the July 30 agreement
The Memorandum of Agreement covers two pillars. This page concerns the first; the second is described in the Company’s Indonesia updates.
・Pillar 1 — United States (this update). GENRÊVER is licensed as a trademark for premium Japanese-origin cosmetics in the U.S. market. Artisans Production provides the formulations; INVITRX supplies ingredients and manufactures at its U.S. GMP-certified facility; the products are sold in the United States.
・Pillar 2 — Indonesia. The parties intend to co-develop clinic-based cell processing center (CPC) and laboratory capabilities alongside GENRÊVER CLINIC in Indonesia, with INVITRX supplying concentrated exosome and conditioned-media products, subject to regulatory approval. See the Indonesia Growth Platform — Operational Update — [link].
Current project status
Project item — Current status
Memorandum of Agreement with INVITRX (July 30, 2026) — Completed
U.S. product planning — Completed
Initial GENRÊVER U.S. product line-up identified — Completed
Final formulation for each product — In progress
Manufacturing scheduling at INVITRX facility — In progress
Regulatory considerations (U.S. cosmetics requirements) — In progress
Related commercial arrangements — In progress
Commencement of manufacturing (targeted within 2026) — Planned
U.S. sales launch — Planned
All targeted dates are subject to the conditions described above and in the Forward-Looking Statements section below.
Next milestones
・Final formulation and specifications for each product in the initial line-up
・Manufacturing schedule confirmed with INVITRX
・Completion of regulatory review for U.S. sale
・Related commercial arrangements finalized
・Commencement of manufacturing (targeted within 2026)
・Announcement of product details and sales channels ahead of launch
Questions investors have asked
Is this an export business? No. The products are manufactured in the United States at INVITRX’s facility, using INVITRX ingredients, and sold in the United States. Japan provides the brand and the formulation. Which products are in the initial line-up? The line-up has been identified but product details will be announced once final formulation and commercial arrangements are complete. Are there sales targets? The Company does not publish revenue or unit forecasts for this collaboration. Progress will be reported by milestone. What could delay manufacturing? Final formulation outcomes, manufacturing scheduling, regulatory considerations, and the negotiation of related commercial arrangements. See the Forward-Looking Statements section below.
Comment from the Chief Executive Officer
“During the past several weeks, we have progressed site development activities in Jakarta and continued product planning discussions with our manufacturing collaborators in the United States and Indonesia.” — Tomoki Nagano, Chief Executive Officer
GENRÊVER brand site
Learn more
For photos, product details and the latest on GENRÊVER, visit the GENRÊVER brand site
www.genrever.com
Related Press release (September 4, 2026): INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives — [IR page link] Indonesia Growth Platform — Operational Update (detailed article) — [link] Product Development Progress Update: Indonesia Cosmetics Collaboration with PT PARVA CANDELA — [link] July 30, 2026 — Strategic collaboration with INVITRX — [link]
About Instinct Bio
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a biotechnology company focused on regenerative medicine, wellness-related technologies, and therapeutic platform development. Website: https://instinct-biot.com/
Forward-Looking Statements
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the manufacture and sale of GENRÊVER-branded products in the United States, potential manufacturing timelines, and the Company’s collaboration with INVITRX. These statements are based on current expectations and are subject to risks and uncertainties, including the outcome of final formulation; manufacturing scheduling and capacity at INVITRX’s facility; regulatory considerations applicable to cosmetics in the United States; the negotiation of related commercial arrangements and definitive agreements; consumer acceptance; competition; the Company’s relationship with INVITRX; and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that the products described herein will be manufactured or launched, or that the collaboration will generate revenue or profit. Forward-looking statements speak only as of the date of this article, and the Company undertakes no obligation to update them except as required by law.
Product descriptions are provided for informational purposes and are subject to change. The products are not yet available for sale. This article does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Contact Information INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. Email: ir@instinct-bro.com Website: https://instinct-biot.com/ Sign up for email alerts on press releases, SEC filings and events at instinct-biot.com/investors.
Source Documents
Follow @BIOT_jp on X for company news and published IR updates.
